中华顶尖财经--信息搜索

信息搜索

信息关键字：医

『查询2022年信息』『查询2021年信息』『查询2020年信息』『查询2019年信息』『查询2018年信息』『查询2017年信息』『查询2016年信息』
『查询2015年信息』『查询2014年信息』『查询2013年信息』『查询2012年信息』『查询2011年信息』『查询2010年信息』『查询2009年信息』

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165]

·医药生物行业周报：开始进入中报的投资博弈期2023-7-11 12:50:20

·诚益通预计上半年业绩同比上升医药生物智能制造业顺势前行2023-7-11 11:36:17

·医药生物投融资双周报：六月国内回暖，礼来收购Biotech2023-7-11 10:59:17

·A股申购|港通医疗(301515.SZ)开启申购近三年经营业绩稳健增长2023-7-11 7:06:10

·我国基本医疗保险参保人数134592万人，参保率稳在95%以上2023-7-10 20:11:38

·医药生物行业新股系列专题报告：多肽原料龙头2023-7-10 19:17:33

·恒瑞医药：子公司获得药物临床试验批准通知书2023-7-10 18:55:56

·美容护理行业周观点：复星医药肉毒素产品上市申请获受理2023-7-10 18:35:52

·医药行业周报：医保续谈政策缓和，持续关注中报业绩预期2023-7-10 17:11:25

·医药生物行业周报：政策叠加新版基药利好，关注儿科中成药2023-7-10 16:50:03

·商贸零售行业研究：锦波生物：重组胶原蛋白领军者、医美发力，北交所7.10申购2023-7-10 15:35:53

·医药生物行业周报：国谈续约规则发布，创新药支付端回暖2023-7-10 15:31:54

·金域医学：携手华为云打造医检行业大模型2023-7-10 14:31:39

·港通医疗（301515）新股概览，7月11日开始网上申购2023-7-10 13:23:47

·医药生物行业跟踪周报：医保谈判药品续约规则更新，新规则利好创新药放量2023-7-10 13:21:00

·【新股】一图读懂港通医疗2023-7-10 13:06:08

·风和医疗一折股权激励创始人套现2500万遭强生起诉专利侵权三年退换货超1800万2023-7-10 11:45:52

·医药生物行业周报：医保谈判续约规则边际改善，有利创新药放量2023-7-10 11:05:20

·商贸零售行业周报：关注华东医药利拉鲁肽获批减重适应症，本周新增重点推荐水羊股份2023-7-10 10:56:48

·医药生物周跟踪：支付新政下，创新可乐观2023-7-9 21:22:21

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165]